Maine ranks 46th in lung cancer cases nationally

Nov.16.2022
Maine ranks 46th in lung cancer cases nationally
Maine's lung cancer rates rank 46th in the US in 2022, with lower survival rates than the national average. Early screening is encouraged.

According to data from the American Lung Association, the "State of Lung Cancer" report for 2022 shows that Maine ranks 46th in the country for its rate of new lung cancer cases.


The annual report released on Tuesday by the American Lung Association highlighted the number of deaths from lung cancer in Maine and examined key indicators, including new cases, survival rates, early diagnosis, surgical treatment, lack of treatment, and screening rates.


A report on the state of lung cancer nationwide has shown a continued increase in survival rates.


The five-year survival rate for lung cancer has increased by 21% from 2014 to 2018, reaching 25%.


In Maine, the American Lung Association has reported that lung cancer survival rates are 23.8% lower than the national average.


Lung cancer screening is crucial for early diagnosis, which can save lives. Unfortunately, in Maine, we have a higher incidence of lung cancer compared to other states and not enough people are receiving this life-saving screening," said Lance Boucher, Director of Public Relations for the American Lung Association in Maine. "We can all help alleviate the burden of lung cancer in Maine. If you are eligible for lung cancer screening, we encourage you to discuss this with your doctor. If you have family members who are eligible, please encourage them to get screened.


Currently, 14.2 million Americans meet the screening guidelines set forth by the US Preventive Services Task Force (USPSTF). According to these guidelines, the American Lung Association states that individuals between the ages of 50 to 80 with a smoking history of 20 pack-years (defined as smoking 1 pack per day for 20 years or 2 packs per day for 10 years) are eligible for lung cancer screening if they are current smokers or have quit within the past 15 years.


The report from the American Lung Association reveals Maine's ranking.


The incidence rate of lung cancer is 70.8 cases per 100,000 people, ranking 46th in the country. The national rate is 56.7 cases per 100,000 people. The survival rate of 23.8% ranks 25th in the country. The national five-year survival rate for lung cancer diagnosis is 25%, and the 25th early detection rate is 25.8%. Only 25.8% of cases are diagnosed in the early stages, which have higher survival rates, nationwide. The 11.8% lung cancer screening rate ranks fifth nationally. By conducting annual low-dose CT scans for high-risk individuals, lung cancer mortality can be reduced by up to 20%. Only 5.8% of high-risk individuals are screened nationally. Surgery ranks eighth nationally, accounting for 23.7%. Lung cancer can typically be treated with surgery if diagnosed early and has not spread. 20.8% of cases receive surgery nationwide. Lack of treatment ranks sixth nationally, accounting for 16.9%. Nationwide, 20.6% of cases do not receive treatment. The American Lung Association's "State of Lung Cancer" report emphasizes the need for Maine to take more action to reduce the burden of lung cancer and encourage everyone to join the effort to end lung cancer.


Declaration:


This article is compiled from third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the veracity and accuracy of the article's contents. The translation of this article is only for communication and research within the industry.


Due to limitations in translation abilities, this article's translation may not fully convey the same meaning as the original. Please refer to the original article for the most accurate information.


2FIRSTS maintains full alignment with the Chinese government's position and statements on any domestic issues, as well as issues involving Hong Kong, Macau, Taiwan, and foreign relations.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22